ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) was down 8.8% on Thursday . The company traded as low as $0.30 and last traded at $0.31. Approximately 3,316,500 shares were traded during mid-day trading, an increase of 187% from the average daily volume of 1,155,480 shares. The stock had previously closed at $0.34.

Separately, Maxim Group reiterated a “hold” rating on shares of ImmunoCellular Therapeutics in a research report on Thursday, August 24th.

WARNING: “ImmunoCellular Therapeutics Ltd (IMUC) Trading Down 8.8%” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at

ImmunoCellular Therapeutics Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Ratings for ImmunoCellular Therapeutics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.